Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Tracking Information
First Submitted Date ICMJE	June 22, 2010
First Posted Date ICMJE	June 23, 2010
Last Update Posted Date	March 20, 2013
Study Start Date ICMJE	July 2010
Actual Primary Completion Date	August 2010 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJE; (submitted: June 22, 2010)	Droxidopa Pharmacokinetics [ Time Frame: 24 hours ]; Blood samples will be collected at the time from 0 to 24 hours. Cmax, Tmax, AUC(0-∞), AUC(0-t), t1/2, and CL/F, will be determined for plasma concentrations of droxidopa in Parts I and II and will also be determined for two of its metabolites (3-OM-droxidopa and norepinephrine) in Part II only.
Original Primary Outcome Measures ICMJE	Same as current
Change History	Complete list of historical versions of study NCT01149629 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE	Not Provided
Original Secondary Outcome Measures ICMJE	Not Provided
Current Other Outcome Measures ICMJE	Not Provided
Original Other Outcome Measures ICMJE	Not Provided
Descriptive Information
Brief Title ICMJE	Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa
Official Title ICMJE	A Randomized, Open-Label, Three-Period, Three-Sequence, Single-Dose Crossover and Separate Three-Daily-Dose Treatment Period Study Comparing the Pharmacokinetic Profiles Following Oral Dosing of 300 mg of Droxidopa in the Fed Versus Fasted State, the Bioequivalence of Three 100 mg Capsules of Droxidopa Versus a Single 300 mg Capsule of Droxidopa, and 300 mg of Droxidopa Given Three Times at Four Hour Intervals in Healthy, Elderly Subjects
Brief Summary	One purpose of this study is to determine if taking droxidopa after eating will have an effect on how the body processes (absorbs and eliminates) the drug in healthy elderly subjects. Another purpose of this study is to see how the body processes (absorbs and eliminates) one 300mg capsule compared to three 100mg capsules. This study will also evaluate how well the body processes (absorbs and eliminates) and tolerates droxidopa when a 300 mg capsule is given 3 times a day for a total dose of 900 mg over the course of one day. Droxidopa is used to treat low blood pressure upon standing in patients with diseases of the nervous system, to prevent low blood pressure in patients with kidney disease during hemodialysis (removal of waste products of the blood), and to treat frozen gait (walking, stepping or running) and dizziness upon standing in patients with Parkinson's disease.
Detailed Description	This is a two-part study. Part I is a randomized, open-label, three-period crossover study in 24 healthy, elderly, male or female subjects. Subjects will be allocated to one of three treatment sequences according to a randomization schedule prepared prior to the start of the study. Each subject will receive a single, oral dose of three 100 mg capsules of droxidopa with 240 mL of water either in the fasted state (Treatment A) or immediately following the consumption of a standardized high-fat meal (Treatment B) and a single, oral dose of one 300 mg capsule of droxidopa with 240 mL of water in the fasted state (Treatment C) on Days 1, 4, and 7. Subjects will be discharged from the research clinic on Day 8 after completing all posttreatment follow-up assessments and will return to the research clinic approximately 1 week later for Part II of the study. Part II of the study is an open-label design where all subjects will receive three doses of 300 mg droxidopa (three 100 mg capsules/dose) at 4 hour intervals and will be followed for a concurrent 24 h period.
Study Type ICMJE	Interventional
Study Phase	Phase 1
Study Design ICMJE	Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition ICMJE	Symptomatic Neurogenic Orthostatic Hypotension
Intervention ICMJE	Drug: Droxidopa One capsule containing 300 mg droxidopa, given once; Drug: Droxidopa 3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals; Drug: Droxidopa 3 capsules each containing 100 mg droxidopa, given once
Study Arms	Active Comparator: Fed Dosing Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules Intervention: Drug: Droxidopa; Active Comparator: Fasted Dosing Subjects fasted prior to receiving 3 x 100mg capsules Intervention: Drug: Droxidopa; Active Comparator: Bioequivalence Subjects fasted prior to receiving 1x 300mg capsule Intervention: Drug: Droxidopa; Active Comparator: TID Dosing Droxidopa 300 mg given TID Intervention: Drug: Droxidopa
Publications *	Chen JJ, Hewitt LA. Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. Drugs R D. 2018 Mar;18(1):77-86. doi: 10.1007/s40268-018-0226-z.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status ICMJE	Completed
Estimated Enrollment ICMJE; (submitted: June 22, 2010)	24
Original Estimated Enrollment ICMJE	Same as current
Actual Study Completion Date	August 2010
Actual Primary Completion Date	August 2010 (Final data collection date for primary outcome measure)
Eligibility Criteria ICMJE	Inclusion Criteria: Provide written consent on an IRB-approved Informed Consent Form (ICF), prior to any study-specific evaluation. Subjects should have the ability to read and understand the ICF, ask for any clarifications from the study staff, and be able to comply with all planned study procedures.; Male or female ≥65 years of age.; Body mass index (BMI) between 18 and 35 kg/m2, inclusive.; If female, not pregnant (or lactating), as evidenced by a negative serum pregnancy test, and is surgically sterile (hysterectomy, bilateral ovariectomy, or bilateral tubal ligation), or at least 2 years postmenopausal.; Ability and willingness to abstain from alcohol from 48 h prior to the first dose until the completion of the study.; No clinically significant abnormalities on the basis of medical history, physical examination, and vital signs unless currently controlled with medical treatment (e.g., a stable medication dosing regimen).; Computerized, 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations, as judged by the investigator.; All values for hematology, clinical chemistry, and urinalysis are normal or if abnormal—are deemed not clinically significant as judged by a physician investigator with documented agreement from the Medical Monitor.; Nonsmoking or have quit smoking at least 6 months prior to dosing. Exclusion Criteria: Presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease not currently controlled with medical treatment (e.g., a stable medication dosing regimen).; Presence of an active malignancy of any type other than nonmelanomatous skin malignancies.; History of relevant drug and/or food allergies.; Recent history (past 5 years) of alcohol abuse or drug addiction.; Required use of concomitant medications that could confound the PK or safety evaluation, such as medications that affect GI function (including proton pump inhibitors or metoclopramide) or vasoconstricting agents (e.g., ephedrine, dihydroergotamine, or midodrine), -triptans (e.g., sumatriptan, naratriptan, zolmitriptan, rizatriptan), halogen-containing anesthetics (e.g., cyclopropane, or halothane), catecholaminecontaining preparations (e.g., isoprenaline), non-selective MAOIs, ergotamine derivatives (except for anti-Parkinson medications), or any drugs with anti-hypertensive properties that in the investigator's opinion, could significantly contribute to the subject's orthostatic hypotension.; Participation in an investigational drug study within 30 days prior to study drug administration.; Donated a unit of blood (500 mL) or plasma within the 30-day period prior to the initial dose of study medication or who intend to donate blood or plasma within a 30-day period following the final dose of study medication.; Positive screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines) or alcohol.; Positive screen for urine cotinine.; Positive screen for hepatitis B surface antigen.; Positive screen for antibodies to hepatitis C virus.; Positive screen for antibodies to human immunodeficiency virus (HIV-1/HIV-2).; Acute illness within 5 days prior to drug administration.; History of coagulation disorder, thrombocytopenia, bleeding tendency, or gastrointestinal bleeding.; Professional or ancillary personnel involved in the study.; In the opinion of the investigator, not suitable for entry into the study.
Sex/Gender	Sexes Eligible for Study: All
Ages	65 Years and older (Older Adult)
Accepts Healthy Volunteers	Yes
Contacts ICMJE	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries ICMJE	United States
Removed Location Countries
Administrative Information
NCT Number ICMJE	NCT01149629
Other Study ID Numbers ICMJE	Droxidopa NOH101
Has Data Monitoring Committee	No
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	Chelsea Therapeutics
Study Sponsor ICMJE	Chelsea Therapeutics
Collaborators ICMJE	Not Provided
Investigators ICMJE	Principal Investigator: Gregory M Haugen, M.D. Cetero Research, San Antonio
PRS Account	Chelsea Therapeutics
Verification Date	March 2013
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP